1. Cisplatin induces differentiation in teratomas derived from pluripotent stem cells
- Author
-
Masahiko Kuroda, Shin-ichiro Ohno, Atsushi Kurata, Koji Fujita, and Masakatsu Takanashi
- Subjects
0301 basic medicine ,Medicine (General) ,ESC, embryonic stem cell ,Adipose tissue ,KSR, knockout serum replacement ,0302 clinical medicine ,ATP4B, ATPase H+/K+ transporting beta subunit ,Induced pluripotent stem cell ,DMEM, Dulbecco's modified Eagle's medium ,HE, hematoxylin and eosin ,LIF, leukemia inhibitory factor ,RLU, relative light units ,Induced pluripotent stem cells ,medicine.anatomical_structure ,ssDNA, single stranded DNA ,Differentiation ,RT, room temperature ,Original Article ,medicine.drug ,iPSC, induced pluripotent stem cell ,Embryonic stem cells ,PCNA, proliferating cell nuclear antigen ,Biomedical Engineering ,Immature teratoma ,Biology ,α-SMA, α-smooth muscle actin ,Biomaterials ,Andrology ,03 medical and health sciences ,R5-920 ,PBS, phosphate buffered saline ,Gastric mucosa ,medicine ,RAG, recombination activating gene ,Cisplatin ,CR, chemotherapeutic retroconversion ,ALP, alkaline phosphatase ,QH573-671 ,medicine.disease ,Embryonic stem cell ,MEF, mouse embryonic fibroblast ,Transplantation ,030104 developmental biology ,FCS, fetal calf serum ,Cytology ,030217 neurology & neurosurgery ,Immunostaining ,Developmental Biology - Abstract
Introduction Currently, embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) can be induced to differentiate at the cellular level but not to form mature tissues or organs suitable for transplantation. ESCs/iPSCs form immature teratomas after injection into immunodeficient mice. In humans, immature teratomas often transform into fully differentiated mature teratomas after administration of anticancer agents. Methods We first investigated the ability of cisplatin to induce changes in mouse ESCs/iPSCs in vitro. Next, we designed experiments to analyze ESC/iPSC-derived immature teratoma tissue in vivo after treatment of cisplatin. Groups of six mice carrying ESC- or iPSC-derived teratomas were given either low or high dose intraperitoneal injection of cisplatin, while the control group received saline for 4 weeks. Results Treatment of ESC/iPSC cultures with cisplatin for 3 days caused a dose-related decrease in cell numbers without inducing any morphological changes to the cells. ESC/iPSC-derived teratomas showed lower growth rates with a significantly higher mature components ratio in a concentration dependent manner after cisplatin treatment (P, Highlights • Transformation of immature to mature teratoma after chemotherapy was verified. • Mice bearing ESC/iPSC-derived immature teratomas were used. • Mice were treated with intraperitoneal injection of cisplatin for 4 weeks. • Newly differentiated structures were found only in the tumors of treated mice. • Cisplatin can induce differentiation in ESC/iPSC-derived immature teratomas.
- Published
- 2021